Brief: Adaptive Biotechnologies Q2 EPS USD -0.17

Adaptive Biotechnologies

05/08/2025 21:05

Overview

Adaptive Biotechnologies Q2 revenue grows 36%, beating analyst expectations, per LSEG data

MRD business achieves profitability with $1.9 mln adjusted EBITDA

Co raises full-year MRD revenue guidance, lowers cash burn targets

Outlook

Adaptive Biotechnologies raises full-year MRD revenue guidance to $190 mln-$200 mln

Company reduces full-year cash burn guidance to $45 mln-$55 mln

Result Drivers

MRD GROWTH - MRD revenue increased 42% year-over-year, contributing 85% of total revenue

CLONOSEQ VOLUME - clonoSEQ test volume grew 37% compared to the prior year

PROFITABILITY ACHIEVED - MRD business reached profitability with $1.9 mln adjusted EBITDA

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$58.88 mln
$49.40 mln (7 Analysts)
Q2 EPS
-$0.17
Q2 Net Income
-$25.59 mln
Q2 Adjusted EBITDA
Beat
-$7.20 mln
-$14.70 mln (3 Analysts)
Q2 Operating Expenses
$83.92 mln
Q2 Operating Income
-$25.04 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $12.50, about 12.7% above its August 4 closing price of $10.91

Press Release: ID:nGNX6C5Pdk

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)